NAD+ For Men: Biomarkers & Clinical Evidence

Last reviewed: May 30, 2026

Last updated: May 30, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

NAD+ (nicotinamide adenine dinucleotide) is a coenzyme critical for cellular energy production, DNA repair, and metabolic regulation in men. NAD+ levels naturally decline with age, declining roughly 50% between ages 40 and 60, which has prompted research into supplementation's potential role in supporting metabolic health.

Understanding NAD+ in the context of individual metabolic biomarkers and genetic factors supports more personalized conversations with healthcare providers. PlexusDx emphasizes precision-wellness approaches that evaluate supplement strategies alongside clinical markers rather than treating them as standalone interventions for longevity.

How NAD+ Functions in Male Cellular and Metabolic Health

NAD+ participates in multiple metabolic pathways including glycolysis, the citric acid cycle, and mitochondrial function. In men, NAD+-dependent sirtuins regulate cellular stress responses, mitochondrial biogenesis, and circadian rhythm regulation—all factors linked to metabolic aging.

Declining NAD+ is associated with reduced mitochondrial efficiency, increased oxidative stress, and metabolic dysfunction. Research in animal models shows NAD+ supplementation supports metabolic flexibility and mitochondrial health, though human clinical data remains limited and context-dependent on individual metabolic status.

NAD+ Precursors and Their Biomarker Implications

NAD+ supplementation typically uses precursors like nicotinamide riboside (NR), nicotinamide mononucleotide (NMN), or niacin. Each precursor enters different metabolic pathways and may influence biomarkers differently based on individual genetic variation and baseline metabolic health. Understanding baseline metabolic markers informs which precursor strategy may be most relevant.

NAD+ Precursor	Primary Pathway	Relevant Biomarkers	Clinical Context
Nicotinamide Riboside (NR)	Salvage pathway	NAD+ levels, mitochondrial markers	Most studied in human trials; oral bioavailability moderate
Nicotinamide Mononucleotide (NMN)	Direct NAD+ synthesis	NAD+ levels, sirtuins, energy metabolism	Emerging human data; mechanism-of-action promising in animals
Niacin (B3)	De novo pathway	NAD+, lipid markers, vascular function	Longest evidence history; affects lipid metabolism and glucose control
Tryptophan	De novo pathway	Kynurenine pathway markers, NAD+ synthesis	Lower bioavailability; influenced by gut microbiome and immune status

Clinical Evidence for NAD+ Supplementation in Men

Human clinical trials on NAD+ supplementation remain limited but growing. A 2021 randomized controlled trial found NMN supplementation improved insulin sensitivity in men with prediabetes, though effect sizes were modest. Most evidence comes from mechanistic animal studies rather than large-scale human outcome trials.

Current evidence supports NAD+ precursors as potentially supportive for metabolic function and mitochondrial health in men, particularly those with metabolic dysfunction or aging-related decline. However, no large randomized trials demonstrate NAD+ reverses aging or extends lifespan in humans. Provider evaluation of baseline metabolic biomarkers helps contextualize whether supplementation aligns with individual health status.

Metabolic Biomarkers and Provider Evaluation Framework

Before considering NAD+ supplementation, providers typically evaluate baseline metabolic status using markers like fasting glucose, insulin sensitivity (HOMA-IR), lipid panel, and mitochondrial function indicators. Men with metabolic dysfunction, low energy, or age-related metabolic decline may represent better candidates for biomarker-guided NAD+ evaluation than asymptomatic men.

A comprehensive provider conversation should address baseline NAD+ status when possible, other metabolic interventions already in place (exercise, sleep, nutrition), and realistic expectations. NAD+ supplementation should integrate into broader metabolic health strategies rather than replace evidence-based lifestyle interventions that naturally support NAD+ synthesis.

Safety, Drug Interactions, and Who Should Consult a Provider

NAD+ precursors are generally well-tolerated in short-term studies, though long-term safety data in humans remains limited. Niacin (B3) can affect lipid metabolism and glucose control, requiring monitoring in men with dyslipidemia or diabetes. NR and NMN have not shown significant adverse effects in clinical trials, but individual response varies.

Men considering NAD+ supplementation should consult a healthcare provider if they take medications affecting lipid or glucose metabolism, have active malignancy, or experience fatigue or metabolic dysfunction. Providers can assess whether NAD+ fits within individual health goals and whether baseline biomarkers support supplementation as part of a precision-wellness strategy.

How PlexusDx Supports a More Personalized Approach

PlexusDx's Precision Peptide Genetic Test may help provide context for metabolic pathways influencing energy production and aging. While the test focuses on peptide-related genetic variants (GLP1R, GIPR, FTO, MC4R), these genes connect to broader metabolic regulation and mitochondrial efficiency—factors relevant to NAD+ metabolism and metabolic aging trajectories.

The Precision Peptide Genetic Test reveals predispositions in pathways linked to metabolic flexibility and glucose regulation, which should be interpreted with a qualified healthcare provider in the context of NAD+ supplementation discussions. Genetic predisposition does not predict exact NAD+ response or supplementation outcomes, but may inform whether metabolic support strategies align with individual genetic and biomarker profiles.

Understanding your genetic predispositions in metabolic pathways, combined with baseline biomarker assessment, can support more informed conversations with your provider about whether NAD+ supplementation fits within your overall precision-wellness strategy. PlexusDx encourages integrating genetic insights with clinical markers to evaluate personalized approaches to metabolic health.

How Your Genetics Influence GLP-1 Response

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month, or $298 standalone) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection starts at $179-$229/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.

Frequently Asked Questions

What is NAD+ and why does it decline with age in men?

NAD+ is a coenzyme essential for cellular energy, DNA repair, and stress responses. Levels decline roughly 50% between ages 40 and 60 due to increased consumption, reduced synthesis, and accumulating cellular damage—factors contributing to metabolic aging.

Does scientific evidence prove NAD+ supplementation extends lifespan in men?

No human studies demonstrate NAD+ supplements extend lifespan. Animal models show metabolic benefits, but human clinical trials are limited and focus on metabolic function rather than longevity outcomes.

How much does NAD+ supplementation cost and how is it administered?

NAD+ precursors (NR, NMN) typically cost $30–100 monthly for oral supplements. Intravenous NAD+ is available through some clinics but carries higher cost and requires medical supervision. Oral options are more accessible for long-term use.

Are there safety concerns or side effects with NAD+ precursors?

NR and NMN show good tolerability in short-term studies. Niacin can affect lipids and glucose control. Long-term human safety data remains limited. Consultation with a provider is recommended, especially for men on metabolic medications.

How does genetic predisposition to metabolic dysfunction relate to NAD+ supplementation?

Genetic variants affecting glucose metabolism and mitochondrial function may influence NAD+ supplementation relevance. PlexusDx's Precision Peptide Genetic Test reveals metabolic pathway predispositions that can inform provider conversations about whether NAD+ fits your personalized health strategy.

NAD+ For Men: Biomarker Context and Clinical Evidence for Metabolic Aging